News and resources search
Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum
MMV's Chief of Corporate Strategy and Affairs Andrea Lucard spoke at "Breaking barriers: The power of inclusive R&D to accelerate malaria elimination," hosted by Devex in partnership with MMV.
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study
Integration and application of new approach methodologies in assessing the developmental hazards: Case study with an antimalarial drug
Advances in Malaria Pharmacology and the online Guide to MALARIA PHARMACOLOGY: IUPHAR Review X
Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline
Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
A video blog from the MMV Peru team following the launch of the PAVE Peru feasibility study in March 2023.
This video showcases the 2022 RBM Malaria in Pregnancy Working Group (MiPWG) Meeting in Accra, Ghana. The MiPWG is a diverse group of stakeholders that convenes annually to share updates on progress to defeat malaria in pregnancy.
Comparative Susceptibility of Plasmodium ovale and Plasmodium falciparum Field Isolates to Reference and Lead Candidate Antimalarial Drugs in Ghana
This short video explores the role of the APMEN Vivax Working Group in the fight against malaria in the Asia-Pacific region.
The impact of community delivery of intermittent preventive treatment of malaria in pregnancy on its coverage in four sub-Saharan African countries (Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria)
Facilitators and barriers to seasonal malaria chemoprevention (SMC) uptake in Nigeria: a qualitative approach
PDPs remain the chief developers of innovative medical technologies for people suffering with diseases and health threats underserved by traditional markets.